Trial reportDrug design, development and therapy2026
Dexmedetomidine Plus Stellate Ganglion Block Improves Postoperative Sleep Quality in Elderly Hip Arthroplasty Patients: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Remimazolam versus Propofol Sedation on Postoperative Sleep Quality Following Gastroscopy: A Propensity Score-Matched Cohort Study.Drug design, development and therapy · 2026Article
- Anesthesia-Informed Approaches to Insomnia: Shared Neural Circuits, Biomimetic Sleep, and Emerging Interventional Strategies.Nature and science of sleep · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the effect of dexmedetomidine combined with stellate ganglion block (SGB) on postoperative sleep quality in elderly patients undergoing hip arthroplasty. Methods: 126 patients aged ≥ 65 years undergoing hip arthroplasty were allocated to three groups: control (Group C), dexmedetomidine (Group D), and dexmedetomidine plus SGB (Group DS). Group D received dexmedetomidine (loading dose 0.5µg/kg over 10 min, then 0.2µg/kg/h infusion until surgery end). Group DS received the same regimen plus SGB at C6 with 5mL of 0.375% ropivacaine. The primary outcome was postoperative sleep quality assessed by the Richards-Campbell Sleep Questionnaire (RCSQ) on the first three postoperative nights. Secondary outcomes included postoperative visual analogue scale (VAS) scores, number of patient-controlled analgesia (PCA) and sleep quality using Pittsburgh Sleep Quality Index (PSQI) scores at one month postoperatively. Results: On the first three postoperative nights (POD 1-3), the RCSQ scores were significantly higher in Groups D and DS compared with Group C ( Conclusion: In elderly patients undergoing hip arthroplasty, dexmedetomidine combined with SGB significantly improved subjective sleep quality during the first three postoperative nights, although this beneficial effect was not maintained at one month postoperatively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.